Search - tctmd.com

Displaying 21 - 40 of 143

Sort: Relevancy | Date

News Conference News ESC 2023

ESC/EACTS Task Force Recommends Downgrading PCI in Left Main CAD

Michael O'Riordan

September 05, 2023

News Conference News ESC 2023

MULTISTARS AMI: Immediate Complete PCI in STEMI as Safe as Staged Revascularization

Michael O'Riordan

August 28, 2023

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

News Daily News

Physiologic Testing May ID Patients Who’ll Still Have Angina After PCI

Michael O'Riordan

March 31, 2023

News Conference News CRT 2023

In CABG/PCI Decisions for Left Main Disease, Diabetes ‘Still Matters’

Yael L. Maxwell

March 01, 2023

News Conference News EuroPCR 2022

Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities

Caitlin E. Cox

May 25, 2022

News Conference News EuroPCR 2022

Intravascular Imaging Boosts Outcomes in Left Main PCI: ROLEX

Michael O'Riordan

May 18, 2022

Podcast TCTMD Talking Points

The COBRA-REDUCE Trial

December 01, 2021

Presentation TCT 2021

The Role of Drug Coated Balloons in Bifurcation Lesions

Presenter: Robert Byrne

November 04, 2021

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

News Conference News TCT 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

L.A. McKeown

November 04, 2021

News Conference News

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

Shelley Wood

August 30, 2021

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Shelley Wood

August 28, 2021

News Conference News CRT 2021

Polymer-Free Stent Noninferior to ZES at 3 Years: ReCre8

Yael L. Maxwell

March 18, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Daily News

Fewer MIs With Prasugrel Than Ticagrelor in STEMI Patients: ISAR-REACT 5

Michael O'Riordan

November 03, 2020

News Industry News

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

October 17, 2020

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

Presentation TCT 2020

COBRA-REDUCE: Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy

Presenter: Robert A. Byrne

October 17, 2020

Presentation TCT 2020

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

Presenter: Robert Byrne

October 17, 2020

Advertisement

ESC/EACTS Task Force Recommends Downgrading PCI in Left Main CAD

MULTISTARS AMI: Immediate Complete PCI in STEMI as Safe as Staged Revascularization

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Physiologic Testing May ID Patients Who’ll Still Have Angina After PCI

In CABG/PCI Decisions for Left Main Disease, Diabetes ‘Still Matters’

Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities

Intravascular Imaging Boosts Outcomes in Left Main PCI: ROLEX

The COBRA-REDUCE Trial

The Role of Drug Coated Balloons in Bifurcation Lesions

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

FAVOR III China Adds Strength to Value of QFR-Guided PCI

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Polymer-Free Stent Noninferior to ZES at 3 Years: ReCre8

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Fewer MIs With Prasugrel Than Ticagrelor in STEMI Patients: ISAR-REACT 5

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

COBRA-REDUCE: Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content